The Opportunity.
Switzerland spends CHF 2.5 billion annually on preventive health, yet remains the only DACH country without a mobile diagnostic fleet.
TAM → SAM → SOM · capital-efficient scaling
No Direct Competitor
No existing mobile fleet operator delivers employer-site preventive screening in Switzerland. The market is uncontested.
50% Cost Advantage
German telemedicine physicians (MEBEKO-recognized) provide clinical oversight at half the cost of Swiss-based doctors, a structural margin advantage.
Regulatory Moat
Institutional ZSR number + QUALAB accreditation + cantonal BAB approval (all targeting accreditation) create a multi-layer regulatory barrier that takes 12–18 months to replicate.
Capital-Efficient Scaling
Each van pays back within 10 months. Fleet expansion is modular: add vans, add cities, add revenue. No facility buildout required.
Four Revenue Streams.
Diversified revenue base across direct employer contracts, mandatory insurance, complementary coverage, and clinical trial recruitment.
Employer B2B
Direct contracts with Swiss employers for on-site preventive screening programmes. Per-employee, per-visit pricing.
LAMal Billing
Mandatory insurance reimbursement for qualifying cardiovascular screenings. Institutional ZSR number required.
VVG Insurance
Complementary insurance partnerships for expanded screening panels. Premium wellness positioning for insurer members.
Trial Recruitment
Clinical trial patient identification and pre-screening for pharma partners. High-margin, data-leveraged revenue.
Detailed Materials Available Under NDA
Our financial model, unit economics, funding structure, regulatory timeline, and exit analysis are available to qualified investors upon signing a non-disclosure agreement.
Financial Model
10-sheet Excel with P&L, cash flow, sensitivity, unit economics
NDA RequiredFunding Structure
Round details, dilution table, cap table, milestone gates
NDA RequiredUnit Economics
Per-patient waterfall, per-van economics, break-even analysis
NDA RequiredRegulatory Pathway
MEBEKO timeline, cantonal licensing, institutional ZSR model
On RequestExit Analysis
Potential acquirers, valuation scenarios, comparable transactions
NDA RequiredFull Whitepaper
30-section clinical, regulatory, and operational business plan
On RequestHow It Works
Request Access
Fill in the form below with your details and investment interest.
Sign NDA
We send you a mutual NDA. Once signed, you receive the full investor package.
Review & Meet
Review the materials, schedule a call with the founding team.
Request Full Prospectus
Access the complete investor materials including financial model, pitch deck, and whitepaper.
Request Received
We will send the prospectus materials to your email within 24 hours.
Includes:
Prevention should meet people where they work.
Switzerland spends CHF 2.5 billion a year on preventive health — yet chronic diseases still account for 80% of healthcare costs. The gap isn't in spending. It's in access.
Ventve brings clinically validated preventive diagnostics directly to Swiss workplaces. A mobile fleet, telemedicine oversight, and results within 24 hours — no clinics, no waiting rooms, no friction.
We exist to make early detection the easiest thing an employee does all year.
Send Us a Message
Questions, partnership ideas, or just want to talk? Reach out directly.
Message Sent
Thanks for reaching out. We'll get back to you within 48 hours.
Prefer email? investors@ventve.com